113.00
1.70 (1.53%)
| Penutupan Terdahulu | 111.30 |
| Buka | 111.30 |
| Jumlah Dagangan | 2,339,841 |
| Purata Dagangan (3B) | 6,876,849 |
| Modal Pasaran | 104,089,174,016 |
| Harga / Pendapatan (P/E Ke hadapan) | 62.89 |
| Harga / Jualan (P/S) | 34.08 |
| Harga / Buku (P/B) | 13.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2025 |
| Margin Keuntungan | -24.23% |
| Margin Operasi (TTM) | -31.62% |
| EPS Cair (TTM) | -0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 29.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 58.52% |
| Nisbah Semasa (MRQ) | 5.15 |
| Aliran Tunai Operasi (OCF TTM) | -527.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.11 B |
| Pulangan Atas Aset (ROA TTM) | -4.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | AKESO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.5 |
| Purata | 1.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| AKESO | 104 B | - | - | 13.98 |
| PHARMARON | 54 B | 0.92% | 20.42 | 2.23 |
| INNOVENT BIO | 146 B | - | 111.97 | 8.89 |
| WUXI BIO | 143 B | - | 31.10 | 2.84 |
| SINO BIOPHARM | 117 B | 1.15% | 27.21 | 2.85 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
|
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Growth |
| % Dimiliki oleh Orang Dalam | 24.58% |
| % Dimiliki oleh Institusi | 28.47% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |